The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease

被引:0
|
作者
Hershenson, Roy [1 ,2 ]
Nardi-Agmon, Inbar [1 ,2 ,3 ]
Leshem-Lev, Dorit [2 ,3 ]
Kornowski, Ran [1 ,2 ]
Eisen, Alon [1 ,2 ]
机构
[1] Rabin Med Ctr, Dept Cardiol, 39 Jabotinsky St, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Felsenstein Med Res Ctr, Petah Tiqwa, Israel
关键词
Diabetes and cardiovascular disease; Endothelial progenitor cells; Cardioprotective effects of anti-diabetic medications; CARDIOVASCULAR OUTCOMES; MIGRATORY ACTIVITY; SGLT-2; INHIBITORS; PERIPHERAL-BLOOD; HEART-FAILURE; RISK-FACTORS; NUMBER; MECHANISMS; GLICLAZIDE; PROFILE;
D O I
10.1186/s12933-024-02466-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDiabetes mellitus (DM) is associated with premature atherosclerotic disease, coronary artery disease (CAD) and chronic heart failure (HF), leading to increased morbidity and mortality. Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) exhibit cardioprotective benefits beyond glucose lowering, reducing the risk of major cardiovascular events (MACE) and HF hospitalizations in patients with DM and CAD. Endothelial progenitor cells (EPCs) are bone marrow-derived cells involved in vascular repair, mobilized in response to vascular injury. The number and function of circulating EPCs (cEPCs) are negatively affected by cardiovascular risk factors, including DM. This study aimed to examine the response of cEPCs to SGLT2i treatment in DM patients with stable CAD.MethodsA prospective single-center study included patients with DM and stable CAD who were started on an SGLT2i (empagliflozin). Peripheral blood samples were collected at baseline, 1 month, and 3 months to evaluate cEPC levels and function by flow cytometry, immunohistochemistry and MTT assays.ResultsEighteen patients were included in the study (median age 73, (IQR 69, 77) years, 67% male). After 1 month of treatment with empagliflozin, there was no significant change in cEPCs level or function. However, following 3 months of treatment, a significant increase was observed both in cell levels (CD34(+)/VEGFR-2(+): from 0.49% (IQR 0.32, 0.64) to 1.58% (IQR 0.93, 1.82), p = 0.0006; CD133(+)/VEGFR-2(+): from 0.38% (IQR 0.27, 0.6) to 0.82% (IQR 0.7, 1.95), p = 0.0001) and in cell function (from 0.25 CFUs (IQR 0, 0.5) at baseline, to 2 CFUs (IQR 1, 2) at 3 months, p = 0.0012).ConclusionsEmpagliflozin treatment in patients with DM and stable CAD increases cEPC levels and function, implying a cardioprotective mechanism. These findings highlight the potential of SGLT2i in treating cardiovascular diseases, warranting further research to explore these effects and their long-term implications.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease
    Eizawa, T
    Ikeda, U
    Murakami, Y
    Matsui, K
    Yoshioka, T
    Takahashi, M
    Muroi, K
    Shimada, K
    HEART, 2004, 90 (06) : 685 - 686
  • [2] Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease
    Vasa, M
    Fichtlscherer, S
    Adler, K
    Aicher, A
    Martin, H
    Zeiher, AM
    Dimmeler, S
    CIRCULATION, 2001, 103 (24) : 2885 - 2890
  • [3] Effect of exercise training in patients with coronary artery disease on circulating endothelial progenitor cells
    Lenk, K
    Adams, V
    Sandri, M
    Tamok, A
    Lenz, D
    Schmidt, A
    Scheinert, D
    Scheinert, D
    Schuler, G
    Hambrecht, R
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 315A - 315A
  • [4] Stable coronary artery disease and endothelial progenitor cells
    Gui, Ya-jun
    Xiang, Qun-yan
    Chen, Jing-yuan
    Wang, Ya-ting
    Hu, Jia-hui
    Chen, Yan-ying
    Liao, Cai-xiu
    Deng, Li-Min
    Xu, Dan-yan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 260 : 18 - 18
  • [5] THE INFLUENCE OF ATORVASTATIN TREATMENT ON CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN CORONARY ARTERY DISEASE PATIENTS
    Semenova, A.
    Dombrovskiy, A.
    Sergienko, I.
    Rvacheva, A.
    Nozadze, D.
    ATHEROSCLEROSIS, 2014, 235 (02) : E123 - E123
  • [6] Circulating endothelial progenitor cells and cardiovascular morbidity and mortality in patients with coronary artery disease
    Werner, N
    Kosiol, S
    Schlegl, T
    Ahlers, P
    Walenta, K
    Link, A
    Nickenig, G
    CIRCULATION, 2005, 112 (17) : U815 - U815
  • [7] Impact of exercise training on circulating endothelial progenitor cells in patients with coronary artery disease
    Adams, V
    Lenk, K
    Sandri, M
    Lenz, D
    Tarnok, A
    Scheinert, D
    Schuler, G
    Hambrecht, R
    EUROPEAN HEART JOURNAL, 2003, 24 : 700 - 700
  • [8] SYNTAX Score is Associated with Circulating Endothelial Progenitor Cells in Patients with Coronary Artery Disease
    Chiang, Chia-Hung
    Leu, Hsin-Bang
    Huang, Po-Hsun
    Chung, Fa-Po
    Huang, Chin-Chou
    Wu, Tao-Cheng
    Chen, Jaw-Wen
    Lin, Shing-Jong
    ACTA CARDIOLOGICA SINICA, 2012, 28 (03) : 216 - 224
  • [9] SYNTAX SCORE IS ASSOCIATED WITH CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH CORONARY ARTERY DISEASE
    Chiung, Chia-Hong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1390 - E1390
  • [10] Circulating endothelial progenitor cells predict coronary artery disease severity
    Kunz, GA
    Liang, G
    Cuculoski, F
    Gregg, D
    Vata, K
    Shaw, L
    Goldschmidt-Clermont, P
    Dong, CM
    Taylor, D
    Peterson, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 496A - 497A